Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.80 billion
- Book Value:
- Revenue TTM:
- $140.73 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
FibroGen Inc had its IPO on 2014-11-14 under the ticker symbol FGEN.
The company operates in the Healthcare sector and Biotechnology industry. FibroGen Inc has a staff strength of 592 employees.
Shares of FibroGen Inc opened at $19.51 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $18.57 - $19.54, and closed at $18.73.
This is a -3.75% slip from the previous day's closing price.
A total volume of 760,499 shares were traded at the close of the day’s session.
In the last one week, shares of FibroGen Inc have increased by +0.7%.
FibroGen Inc's Key Ratios
FibroGen Inc has a market cap of $1.80 billion, indicating a price to book ratio of 53.8258 and a price to sales ratio of 11.2679.
In the last 12-months FibroGen Inc’s revenue was $140.73 million with a gross profit of $-159212000 and an EBITDA of $-290420992. The EBITDA ratio measures FibroGen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, FibroGen Inc’s operating margin was -213.9% while its return on assets stood at -27.19% with a return of equity of -258.01%.
In Q4, FibroGen Inc’s quarterly earnings growth was a positive 53.6% while revenue growth was a positive 107.7%.
FibroGen Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.16 per share while it has a forward price to earnings multiple of 61.3497 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into FibroGen Inc’s profitability.
FibroGen Inc stock is trading at a EV to sales ratio of 8.9498 and a EV to EBITDA ratio of -3.1167. Its price to sales ratio in the trailing 12-months stood at 11.2679.
FibroGen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $610.09 million
- Total Liabilities
- $273.56 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
FibroGen Inc ended 2023 with $610.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $610.09 million while shareholder equity stood at $-21447000.00.
FibroGen Inc ended 2023 with $0 in deferred long-term liabilities, $273.56 million in other current liabilities, 942000.00 in common stock, $-1557688000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $155.70 million and cash and short-term investments were $422.01 million. The company’s total short-term debt was $10,292,000 while long-term debt stood at $0.
FibroGen Inc’s total current assets stands at $492.83 million while long-term investments were $9.41 million and short-term investments were $266.31 million. Its net receivables were $16.30 million compared to accounts payable of $30.76 million and inventory worth $40.44 million.
In 2023, FibroGen Inc's operating cash flow was $0 while its capital expenditure stood at $333000.
Comparatively, FibroGen Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
FibroGen Inc stock is currently trading at $18.73 per share. It touched a 52-week high of $25.69 and a 52-week low of $25.69. Analysts tracking the stock have a 12-month average target price of $24.83.
Its 50-day moving average was $21.66 and 200-day moving average was $16.05 The short ratio stood at 4.83 indicating a short percent outstanding of 0%.
Around 802.5% of the company’s stock are held by insiders while 8055.9% are held by institutions.
Frequently Asked Questions About FibroGen Inc
Similar Industry Stocks (Biotechnology)
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.